Director Dealing

RNS Number : 7970M

BiVictriX Therapeutics PLC

23 September 2021

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

23 September 2021

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or "the Company")

Director Dealing

Alderley Park, 23 September 2021   BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience, announces the following dealing in the  Company's ordinary shares of 1 pence each ("Ordinary Shares").

On 22 September 2021, Mr Iain Ross, the Company's Non-Executive Chairman, purchased 100,000 Ordinary Shares at a weighted average price of 19.42 pence each.

Following the transaction, Mr Ross is benefically interested in 300,000 Ordinary Shares, representing 0.45% of the Company's total issued share capital.  

-Ends-

For more information, please contact: BiVictriX Therapeutics plc Tiffany Thorn, Chief Executive Officer Iain Ross, Chairman Email: [e-mail] SP Angel Corporate Finance LLP (NOMAD and Broker) Tel: [phone] David Hignell, Caroline Rowe (Corporate Finance) Vadim Alexandre, Rob Rees (Sales and Broking) Consilium Strategic Communications Ashley Tapp, Suki Virji, Priit Piip Tel: [phone] Email: [e-mail]

About BiVictriX Therapeutics plc

BiVictriX is a UK-based drug discovery and development company which is focused on leveraging clinical experience to develop a class of highly selective, next generation cancer therapeutics which exhibit superior potency, whilst eliminating treatment-related toxicities.

The Company utilises a first-in-class approach to generate a proprietary pipeline of Bi-Cygni® therapeutics which are designed to selectively target antigen co-expression fingerprints, or "twin antigens", on tumour cells, which are largely absent from healthy cells. Whereas this concept has been validated in a clinical diagnostic setting to support the diagnosis and monitoring of haematological cancers, it has not yet been widely used in a therapeutic setting.

BiVictriX has identified a diverse panel of novel cancer-specific "twin antigens", across a broad range of cancer indications including Diffuse Large B Cell Lymphoma, Acute Myeloid Leukaemia and Blastic Plasmacytoid Dendritic Cell Neoplasm. The Company is using these novel "twin-antigens" to develop more effective and safer therapeutics to target cancers that are expected to constitute orphan indications and currently constitute areas of high unmet medical need.

Find out more about BiVictriX online at www.bivictrix.com  

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Iain Ross
2.	Reason for the Notification
a)	Position/status	Non-Executive Chairman
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	BiVictriX Therapeutics plc
b)	LEI	213800ZI85IZNA6N3L53
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Ordinary Shares of 1 pence each GB00BNXH3K91
	Identification code
b)	Nature of the transaction	Purchase of 100,000 Ordinary Shares
c)	Price(s) and volume(s)	Price(s) Volume(s) 1.  19.375 pence 2.  19.45 pence 3.  19.45 pence  43,507 30,848 25,645
d)	Aggregated information: -   Aggregated volume -   Price	Price(s) Volume(s) 19.42p (weighted average) 100,000
e)	Date of the transaction	22 September 2021
f)	Place of the transaction	AIM, London Stock Exchange

 

END

 

 

DSHBBGDCISDDGBX